Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 79Carcinoma, Renal Cell 36Neoplasms 35Liver Neoplasms 22Carcinoma, Non-Small-Cell Lung 7Carcinoma 7Neoplasm Metastasis 6Melanoma 5Thyroid Neoplasms 4Kidney Neoplasms 4Breast Neoplasms 3Financial Stress 2Vaccinia 1Stomach Neoplasms 1Patient Preference 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lymphoma 1Lung Neoplasms 1Liver Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulin-Like Growth Factor I, Resistance To 1Hypophosphatemia 1Hepatitis C 1Hepatitis B 1Glioblastoma 1Digestive System Neoplasms 1

Interventions

Bevacizumab 6Paclitaxel 5Leucovorin 5Irinotecan 5Fluorouracil 5napabucasin 4Gemcitabine 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Ocoxin 3Imatinib Mesylate 3Drug Therapy 3palbociclib 2entinostat 2encorafenib 2Oxaliplatin 2Levoleucovorin 2Folfox protocol 2Everolimus 2Cisplatin 2Cetuximab 25,10-methylenetetrahydrofolic acid 2spartalizumab 1ribociclib 1repotrectinib 1pralsetinib 1pembrolizumab 1olaparib 1linifanib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Digestive System Neoplasms × Sorafenib × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡